Long-Term Effects of Donepezil on P300 Auditory Event-Related Potentials in Patients with Alzheimer’s Disease

Abstract

The P300, one of the cognitive event-related potentials (ERPs) of the cerebral cortex, reflects the functioning of the neurochemical system involved in cognitive processes. We investigated clinical significance of the components of auditory P300 ERPs, in comparison with neuropsychologic tests including the Mini-Mental State Examination and the Japanese version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-J cog), for evaluating of the effect of donepezil (DPZ) (5 mg daily for 6 months), an acetylcholinesterase inhibitor, in patients with Alzheimer’s disease (AD). Reduction of P300 latency associated with a parallel improvement of ADAS-J cog scores was observed after administration of 5 mg/day of DPZ in patients with AD. P300 latency gives very useful information on the progression of AD, especially in the longitudinal follow-up of patients with AD during treatment with DPZ acting on cholinergic pathways. (J Geriatr Psychiatry Neurol 2003;16:39-43)

Get full access to this article

View all access options for this article.

References

1. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137-147.

2. Mohs RC, Rosen WG, Davis KL. The Alzheimer’s Disease Assessment Scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983; 19: 448-450.

3. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12: 189-198.

4. Jagust WJ. Neuroimaging in dementia. Neurol Clin 2000; 18: 885-902.

5. Fernandez LA, Penzol DF, Morales RM. Neurophysiological study and use of P300 evoked potentials for investigation in the diagnosis and follow-up of patients with Alzheimer’s disease. Rev Neurol 2001; 32: 525-528.

6. Polich J, Kok A. Cognitive and biologic determinants of P300: an integrative review. Bio Psychol 1995; 41: 103-146.

7. Meador KG, Loring DW, Sethi KD, et al. Cholinergic and serotonergic effects on the P3 potential and recent memory. J Clin Exp Neuropsychol 1989; 11: 252-260.

8. Bryson HM, Benfield P. Donepezil. Drugs & Aging 1997; 10: 234-239.

9. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: reports of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-944.

10.

10. Clair DS, Blackburn I, Blackwood D, Tyrer G. Measuring the course of Alzheimer’s disease: a longitudinal study of neuropsychological function and changes in P3 event-related potential. Br J Psychiatr 1988; 152: 48-54.

11.

11. Homma A, Fukuzawa K, Tsukada Y, et al. Development of a Japanese version of Alzheimer’s disease assessment scale (ADAS). Jpn J Geriatr Psychiatry 1992; 3: 647-655.

12.

12. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. Arch Intern Med 1998; 158: 1021-1031.

13.

13. Thomas A, Iacono D, Bonanni L, et al. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 eventrelated potential/neuropsychologic evaluation over 6 months. Clin Neuropharmacol 2001; 24: 31-42.

14.

14. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer’s disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dement Geriatr Cogn Disord 2000; 11: 299-313.

15.

15. Reeves RR, Struve FA, Patricks G, et al. The effects of donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer’s disease. Am J Geriatr Psychiatry 1999; 7: 349-352.

16.

16. Polich J, Ladish C, Bloom FE. P300 assessment of early Alzheimer’s disease. Electroenceph Clin Neurophysiol 1990; 77: 179-189.